A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT07265284 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: IBI112
DRUG: placebo

Sponsor

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.